Taylor JS, et al. - Researchers investigated if race impacts whether or not patients receive optimal treatment for ovarian cancer and how this influences overall survival. They identified women 66 years and older diagnosed with advanced ovarian cancer between 2002 and 2011 from the SEER-linked Medicare database. They excluded patients with unclear histology, diagnosed on autopsy and without Medicare Parts A and B. Overall, they examined 9,016 ovarian cancer patients, with 2,638 treated with primary chemotherapy, 4,854 having primary surgery, and 1,524 that did not receive any treatment. According to findings, non-white women had a lower likelihood of getting standard of care treatment for ovarian cancer. Furthermore, these women, in comparison to white women, were more likely to die from their disease. Black and Hispanic patients were less likely to receive both chemotherapy and surgery, on multivariable analysis.